+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Dravet Syndrome Market Insights, Epidemiology, and Market Forecast - 2030

  • ID: 5129093
  • Report
  • July 2020
  • Region: Global
  • 143 Pages
  • DelveInsight

FEATURED COMPANIES

  • Biocodex
  • GW Pharmaceuticals
  • Ovid Therapeutics
  • PTC Therapeutics
  • Zogenix
  • MORE

‘Dravet Syndrome Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Dravet Syndrome (DS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Dravet Syndrome market report provides analysis regarding current treatment practices, emerging drug-like Cannabidiol, potential therapies, market share of the individual therapies, historical, current and forecasted Dravet Syndrome market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Dravet Syndrome treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Dravet Syndrome - Disease Understanding and Treatment Algorithm

Dravet Syndrome Overview

Dravet Syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.

It occupies a very distinct place among rare and severe epilepsies, which is quite evident from the names it was given during its short and eventful history. Initially “Severe myoclonic epilepsy of infancy” (SMEI) was distinguished from Lennox-Gastaut syndrome (LGS) which was then considered as the most common severe epilepsy of childhood, and with which it shared pharmacoresistance, episodes of status epilepticus (SE) and intellectual disability.

Dravet Syndrome Treatment

This chapter covers the details of conventional and current medical therapies available in the Dravet Syndrome market for the treatment of the condition. It also provides the country-wise Dravet Syndrome treatment guidelines across the United States, Europe and Japan.

The Dravet Syndrome market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Dravet Syndrome treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Dravet Syndrome Epidemiology

The Dravet Syndrome epidemiology chapters provide insights about historical and current Dravet Syndrome patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Incidence of Dravet Syndrome segments Dravet Syndrome epidemiology, Mutation positive cases, Mutation Cases by Types and Class, Seizures associated with Dravet Syndrome, Gender-specific cases and Age-specific cases of Dravet Syndrome. The report includes thorough analysis of all segmentations.

Mutation Positive Cases in Dravet Syndrome can be divided into two subtypes: by types (SCN1A mutation associated with DS and other rare mutations associated with DS) and by class (Missense, Nonsense, Frameshift, Splice site, Inframe Insertion/Deletion and Gross Rearrangements). In the US, the cases of mis-sence mutation in Dravet Syndrome were found to be 6,734 in 2017. Moreover, the cases of SCN1A mutation associated with DS were reported to be 13,175 in the country.

According to the publisher's, the total incident population of Dravet Syndrome in seven major markets was 30,820 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, the United States accounts for the highest number of Dravet Syndrome cases.

Dravet Syndrome Drug Chapters

Drug chapter segment of the Dravet Syndrome report encloses the detailed analysis of Dravet Syndrome pipeline drug. It also helps to understand the Dravet Syndrome clinical trial details, expressive pharmacological action, agreements of included drug and the latest news and press releases.

The primary aim in managing patients with DS is to significantly reduce seizure frequency (particularly prolonged events) and limit antiepileptic drug toxicity First-line management typically involves either valproic acid or clobazam. Zogenix's ZX008, Ovid/Takeda's Soticlestat and PTC Therapeutics's Ataluren are the only therapies in pipeline.

Dravet Syndrome Market Outlook

The Dravet Syndrome market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounts for the highest Dravet Syndrome market size. Among EU5 countries, the United Kingdom had the highest market size with USD 3.9 million in 2017, while Spain had the lowest market size of DS with USD 1.9 million in 2017.

Dravet Syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Dravet Syndrome market or expected to get launched in the market during the study period 2017-2030. The analysis covers Dravet Syndrome market uptake by drugs; patient uptake by therapies; and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of DS market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Dravet Syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Dravet Syndrome key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of Dravet Syndrome collaborations, acquisition and merger, licensing, patent details and other information for Dravet Syndrome emerging therapies.

Reimbursement Scenario in Dravet Syndrome

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Dravet Syndrome domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Dravet Syndrome Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biocodex
  • GW Pharmaceuticals
  • Ovid Therapeutics
  • PTC Therapeutics
  • Zogenix
  • MORE
1 Key Insights

2 Executive Summary of Dravet Syndrome

3 SWOT Analysis for Dravet Syndrome

4 Dravet Syndrome Market Overview at a Glance
4.1 Market Share (%) Distribution of Dravet Syndrome in 2017
4.2 Market Share (%) Distribution of Dravet Syndrome in 2030

5 Dravet Syndrome: Disease Background and Overview
5.1 Introduction
5.2 Clinical Features of Dravet Syndrome
5.2.1 Epilepsy
5.2.2 Cognition
5.2.3 Movement disorders
5.2.4 Sudden Death
5.3 Genetics of Dravet Syndrome
5.3.1 Sodium Channel a1 Subunit Gene (SCN1A) and its association with Dravet Syndrome
5.3.2 Functional aspects of voltage gate sodium channel mutations
5.3.3 Detection of SCN1A mutations
5.3.4 Inheritance mode and pattern
5.3.5 Dravet Syndrome without SCN1A Alterations
5.4 Signs and Symptoms of Dravet Syndrome
5.5 Pathophysiology
5.6 Diagnosis of Dravet Syndrome
5.6.1 Differential diagnosis

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Total Incidence of Dravet Syndrome in 7MM

7 Country Wise-Epidemiology of Dravet Syndrome

8 United States
8.1 Assumptions and Rationale
8.2 Incident Population of Dravet Syndrome
8.3 Mutations associated with Dravet Syndrome
8.3.1 Incidence of Dravet Syndrome by Mutation Class
8.3.2 Incidence of Dravet Syndrome by Mutation Type
8.4 Seizure associated cases of Dravet Syndrome
8.5 Gender-specific Incidence of Dravet Syndrome
8.6 Age-specific Incidence of Dravet Syndrome

9 EU-5
9.1 Assumptions and Rationale

10 Germany
10.1 Incident Population of Dravet Syndrome
10.2 Mutations associated with Dravet Syndrome
10.2.1 Incidence of Dravet Syndrome by Mutation Class
10.2.2 Incidence of Dravet Syndrome by Mutation Type
10.3 Seizure associated cases of Dravet Syndrome
10.4 Gender-specific Incidence of Dravet Syndrome
10.5 Age-specific Incidence of Dravet Syndrome

11 France
11.1 Incident Population of Dravet Syndrome
11.2 Mutations associated with Dravet Syndrome
11.2.1 Incidence of Dravet Syndrome by Mutation Class
11.2.2 Incidence of Dravet Syndrome by Mutation Type
11.3 Seizure associated cases of Dravet Syndrome
11.4 Gender-specific Incidence of Dravet Syndrome
11.5 Age-specific Incidence of Dravet Syndrome

12 Italy
12.1 Incident Population of Dravet Syndrome
12.2 Mutations associated with Dravet Syndrome
12.2.1 Incidence of Dravet Syndrome by Mutation Class
12.2.2 Incidence of Dravet Syndrome by Mutation Type
12.3 Seizure associated cases of Dravet Syndrome
12.4 Gender-specific Incidence of Dravet Syndrome
12.5 Age-specific Incidence of Dravet Syndrome

13 Spain
13.1 Incident Population of Dravet Syndrome
13.2 Mutations associated with Dravet Syndrome
13.2.1 Incidence of Dravet Syndrome by Mutation Class
13.2.2 Incidence of Dravet Syndrome by Mutation Type.
13.3 Seizure associated cases of Dravet Syndrome
13.4 Gender-specific Incidence of Dravet Syndrome
13.5 Age-specific Incidence of Dravet Syndrome

14 United Kingdom
14.1 Incident Population of Dravet Syndrome
14.2 Mutations associated with Dravet Syndrome
14.2.1 Incidence of Dravet Syndrome by Mutation Class
14.2.2 Incidence of Dravet Syndrome by Mutation Type
14.3 Seizure associated cases of Dravet Syndrome
14.4 Gender-specific Incidence of Dravet Syndrome
14.5 Age-specific Incidence of Dravet Syndrome

15 Japan
15.1 Assumptions and Rationale
15.2 Incident Population of Dravet Syndrome
15.3 Mutations associated with Dravet Syndrome
15.3.1 Incidence of Dravet Syndrome by Mutation Class
15.3.2 Incidence of Dravet Syndrome by Mutation Type
15.4 Seizure associated cases of Dravet Syndrome
15.5 Gender-specific Incidence of Dravet Syndrome
15.6 Age-specific Incidence of Dravet Syndrome

16 Treatment of Dravet Syndrome
16.1 Current Treatment Practices
16.1.1 First-Line Therapies: Valproic Acid and Clobazam
16.1.2 Second-Line Therapies
16.1.3 Third Line of Therapies
16.2 Treatment Algorithm

17 Unmet Needs

18 Organizations contributing toward Dravet Syndrome

19 KOL’s Views: Dravet Syndrome

20 Case Studies
20.1 Anesthetic Management of Dravet Syndrome
20.2 Dravet Syndrome and Parkinsonism

21 Marketed Drugs
21.1 Diacomit: Biocodex
21.1.1 Drug Description
21.1.2 Mechanism of Action
21.1.3 Regulatory Milestones
21.1.4 Advantages and Disadvantages
21.1.5 Safety and Efficacy
21.2 Epidiolex: GW Pharmaceuticals
21.2.1 Drug Description
21.2.2 Mechanism of Action
21.2.3 Regulatory Milestones
21.2.4 Advantages and Disadvantages
21.2.5 Safety and Efficacy

22 Emerging Therapies
22.1 ZX-008: Zogenix
22.1.1 Product Description
22.1.2 Other Development Activities
22.1.3 Clinical Development
22.1.4 Safety and Efficacy
22.1 Soticlestat: Ovid Therapeutics
22.1.1 Product Description
22.1.2 Other Development Activities
22.1.3 Clinical Development
22.1.4 Safety and Efficacy
22.2 Ataluren: PTC Therapeutics
22.2.1 Product Description
22.2.2 Clinical Development

23 Dravet Syndrome: Seven Major Market Analysis
23.1 Key Findings
23.2 Total Market Size of Dravet Syndrome in 7MM

24 Market Outlook by Country
24.1 The United States: Market Outlook
24.2 United States Market Size
24.2.1 Total Market Size of Dravet Syndrome
24.2.2 Dravet Syndrome Market Size by Therapies
24.3 EU-5 Countries: Market Outlook
24.4 Germany Market Size
24.4.1 Total Market Size of Dravet Syndrome
24.4.2 Dravet Syndrome Market Size by Therapies
24.5 France Market Size
24.5.1 Total Market Size of Dravet Syndrome
24.5.2 Dravet Syndrome Market Size by Therapies
24.6 Italy Market Size
24.6.1 Total Market Size of Dravet Syndrome
24.6.2 Dravet Syndrome Market Size by Therapies
24.7 Spain Market Size
24.7.1 Total Market Size of Dravet Syndrome
24.7.2 Dravet Syndrome Market Size by Therapies
24.8 The United Kingdom Market Size
24.8.1 Total Market Size of Dravet Syndrome
24.8.2 Dravet Syndrome Market Size by Therapies
24.9 Japan: Market Outlook
24.1 Japan: Market Size
24.10.1 Total Market Size of Dravet Syndrome
24.10.2 Dravet Syndrome Market Size by Therapies

25 Market Drivers

26 Market Barriers

27 Appendix

28 Report Methodology
28.1 Sources Used

29 Capabilities

30 Disclaimer

31 About the Publisher

List of Tables
Table 1: Genetic background of Dravet syndrome
Table 2: Total Incident Population of Dravet Syndrome in 7MM (2017–2030)
Table 3: Incident Population of Dravet Syndrome in the United States (2017–2030)
Table 4: Mutation positive cases of Dravet Syndrome in the United States (2017–2030)
Table 5: Incidence of Dravet Syndrome by Mutation Class in the United States (2017–2030)
Table 6: Incidence of Dravet Syndrome by Mutation Type in the United States (2017–2030)
Table 7: Seizure associated cases of Dravet Syndrome in the United States (2017–2030)
Table 8: Gender-specific Incidence of Dravet Syndrome in the United States (2017–2030)
Table 9: Age-specific Incidence of Dravet Syndrome in the United States (2017–2030)
Table 10: Incident Population of Dravet Syndrome in Germany (2017–2030)
Table 11: Mutation positive cases of Dravet Syndrome in Germany (2017–2030)
Table 12: Incidence of Dravet Syndrome by Mutation Class in Germany (2017–2030)
Table 13: Incidence of Dravet Syndrome by Mutation Type in Germany (2017–2030)
Table 14: Seizure associated cases of Dravet Syndrome in Germany (2017–2030)
Table 15: Gender-specific Incidence of Dravet Syndrome in Germany (2017–2030)
Table 16: Age-specific Incidence of Dravet Syndrome in Germany (2017–2030)
Table 17: Incident Population of Dravet Syndrome in France (2017–2030)
Table 18: Mutation positive cases of Dravet Syndrome in France (2017–2030)
Table 19: Incidence of Dravet Syndrome by Mutation Class in France (2017–2030)
Table 20: Incidence of Dravet Syndrome by Mutation Type in France (2017–2030)
Table 21: Seizure associated cases of Dravet Syndrome in France (2017–2030)
Table 22: Gender-specific Incidence of Dravet Syndrome in France (2017–2030)
Table 23: Age-specific Incidence of Dravet Syndrome in France (2017–2030)
Table 24: Incident Population of Dravet Syndrome in Italy (2017–2030)
Table 25: Mutation positive cases of Dravet Syndrome in Italy (2017–2030)
Table 26: Incidence of Dravet Syndrome by Mutation Class in Italy (2017–2030)
Table 27: Incidence of Dravet Syndrome by Mutation Type in Italy (2017–2030)
Table 28: Seizure associated cases of Dravet Syndrome in Italy (2017–2030)
Table 29: Gender-specific Incidence of Dravet Syndrome in Italy (2017–2030)
Table 30: Age-specific Incidence of Dravet Syndrome in Italy (2017–2030)
Table 31: Incident Population of Dravet Syndrome in Spain (2017–2030)
Table 32: Mutation positive cases of Dravet Syndrome in Spain (2017–2030)
Table 33: Incidence of Dravet Syndrome by Mutation Class in Spain (2017–2030)
Table 34: Incidence of Dravet Syndrome by Mutation Type in Spain (2017–2030)
Table 35: Seizure associated cases of Dravet Syndrome in Spain (2017–2030)
Table 36: Gender-specific Incidence of Dravet Syndrome in Spain (2017–2030)
Table 37: Age-specific Incidence of Dravet Syndrome in Spain (2017–2030)
Table 38: Incident Population of Dravet Syndrome in the United Kingdom (2017–2030)
Table 39: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017–2030)
Table 40: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017–2030)
Table 41: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017–2030)
Table 42: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017–2030)
Table 43: Gender-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)
Table 44: Age-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)
Table 45: Incident Population of Dravet Syndrome in Japan (2017–2030)
Table 46: Mutation positive cases of Dravet Syndrome in Japan (2017–2030)
Table 47: Incidence of Dravet Syndrome by Mutation Class in Japan (2017–2030)
Table 48: Incidence of Dravet Syndrome by Mutation Type in Japan (2017–2030)
Table 49: Seizure associated cases of Dravet Syndrome in Japan (2017–2030)
Table 50: Gender-specific Incidence of Dravet Syndrome in Japan (2017–2030)
Table 51: Age-specific Incidence of Dravet Syndrome in Japan (2017–2030)
Table 52: Organizations contributing towards Dravet Syndrome
Table 53: Seven Major Market Size of Dravet Syndrome in USD Million (2017–2030)
Table 54: 7MM Size of Dravet Syndrome by Therapies in USD Million (2017–2030)
Table 55: The US Market Dravet Syndrome in USD Million (2017–2030)
Table 56: The US Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 57: Germany Market of Dravet Syndrome in USD Million (2017–2030)
Table 58: Germany Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 59: France Market of Dravet Syndrome in USD Million (2017–2030)
Table 60: France Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 61: Italy Market of Dravet Syndrome in USD Million (2017–2030)
Table 62: Italy Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 63: Spain Market of Dravet Syndrome in USD Million (2017–2030)
Table 64: Spain Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 65: UK Market of Dravet Syndrome in USD Million (2017–2030)
Table 66: UK Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Table 67: Japan Market of Dravet Syndrome in USD Million (2017–2030)

List of Figures
Figure 1: Schematic representation of clinical manifestations of Dravet syndrome
Figure 2: Differential diagnosis of Dravet syndrome in the course of the disease
Figure 3: Total Incident Population of Dravet Syndrome in 7 MM (2017–2030)
Figure 4: Incident Population of Dravet Syndrome in the United States (2017–2030)
Figure 5: Mutation positive cases of Dravet Syndrome in the United States (2017–2030)
Figure 6: Incidence of Dravet Syndrome by Mutation Class in the United States (2017–2030)
Figure 7: Incidence of Dravet Syndrome by Mutation Type in the United States (2017–2030)
Figure 8: Seizure associated cases of Dravet Syndrome in the United States (2017–2030)
Figure 9: Gender-specific Incidence of Dravet Syndrome in the United States (2017–2030)
Figure 10: Age-specific Incidence of Dravet Syndrome in the United States (2017–2030)
Figure 11: Incident Population of Dravet Syndrome in Germany (2017–2030)
Figure 12: Mutation positive cases of Dravet Syndrome in Germany (2017–2030)
Figure 13: Incidence of Dravet Syndrome by Mutation Class in Germany (2017–2030)
Figure 14: Incidence of Dravet Syndrome by Mutation Type in Germany (2017–2030)
Figure 15: Seizure associated cases of Dravet Syndrome in Germany (2017–2030)
Figure 16: Gender-specific Incidence of Dravet Syndrome in Germany (2017–2030)
Figure 17: Age-specific Incidence of Dravet Syndrome in Germany 2017–2030)
Figure 18: Incident Population of Dravet Syndrome in France (2017–2030)
Figure 19: Mutation positive cases of Dravet Syndrome in France (2017–2030)
Figure 20: Incidence of Dravet Syndrome by Mutation Class in France (2017–2030)
Figure 21: Incidence of Dravet Syndrome by Mutation Type in France (2017–2030)
Figure 22: Seizure associated cases of Dravet Syndrome in France (2017–2030)
Figure 23: Gender-specific Incidence of Dravet Syndrome in France (2017–2030)
Figure 24: Age-specific Incidence of Dravet Syndrome in France (2017–2030)
Figure 25: Incident Population of Dravet Syndrome in Italy (2017–2030)
Figure 26: Mutation positive cases of Dravet Syndrome in Italy (2017–2030)
Figure 27: Incidence of Dravet Syndrome by Mutation Class in Italy (2017–2030)
Figure 28: Incidence of Dravet Syndrome by Mutation Type in Italy (2017–2030)
Figure 29: Seizure associated cases of Dravet Syndrome in Italy (2017–2030)
Figure 30: Gender-specific Incidence of Dravet Syndrome in Italy (2017–2030)
Figure 31: Age-specific Incidence of Dravet Syndrome in Italy (2017–2030)
Figure 32: Incident Population of Dravet Syndrome in Spain (2017–2030)
Figure 33: Mutation positive cases of Dravet Syndrome in Spain (2017–2030)
Figure 34: Incidence of Dravet Syndrome by Mutation Class in Spain (2017–2030)
Figure 35: Incidence of Dravet Syndrome by Mutation Type in Spain (2017–2030)
Figure 36: Seizure associated cases of Dravet Syndrome in Spain (2017–2030)
Figure 37: Gender-specific Incidence of Dravet Syndrome in Spain (2017–2030)
Figure 38: Age-specific Incidence of Dravet Syndrome in Spain (2017–2030)
Figure 39: Incident Population of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 40: Mutation positive cases of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 41: Incidence of Dravet Syndrome by Mutation Class in the United Kingdom (2017–2030)
Figure 42: Incidence of Dravet Syndrome by Mutation Type in the United Kingdom (2017–2030)
Figure 43: Seizure associated cases of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 44: Gender-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 45: Age-specific Incidence of Dravet Syndrome in the United Kingdom (2017–2030)
Figure 46: Incident Population of Dravet Syndrome in Japan (2017–2030)
Figure 47: Mutation positive cases of Dravet Syndrome in Japan (2017–2030)
Figure 48: Incidence of Dravet Syndrome by Mutation Class in Japan (2017–2030)
Figure 49: Incidence of Dravet Syndrome by Mutation Type in Japan (2017–2030)
Figure 50: Seizure associated cases of Dravet Syndrome in Japan (2017–2030)
Figure 51: Gender-specific Incidence of Dravet Syndrome in Japan (2017–2030)
Figure 52: Age-specific Incidence of Dravet Syndrome in Japan (2017–2030)
Figure 53: Treatment algorithm of epilepsy in Dravet syndrome.
Figure 54: Unmet Needs for Dravet Syndrome
Figure 55: Seven Major Market Size of Dravet Syndrome in USD Million (2017–2030)
Figure 56: Market Size of Dravet Syndrome in the United States, USD Millions (2017–2030)
Figure 57: The US Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 58: Market Size of Dravet Syndrome in Germany, USD Millions (2017–2030)
Figure 59: Germany Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 60: Market Size of Dravet Syndrome in France, USD Millions (2017–2030)
Figure 61: France Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 62: Market Size of Dravet Syndrome in Italy, USD Millions (2017–2030)
Figure 63: Italy Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 64: Market Size of Dravet Syndrome in Spain, USD Millions (2017–2030)
Figure 65: Spain Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 66: Market Size of Dravet Syndrome in the UK, USD Millions (2017–2030)
Figure 67: The UK Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 68: Market Size of Dravet Syndrome in Japan, USD Millions (2017–2030)
Figure 69: Japan Dravet Syndrome Market Size by Therapies in USD Million (2017–2030)
Figure 70: Market Drivers of Dravet Syndrome
Figure 71: Market Barriers of Dravet Syndrome
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Biocodex
  • GW Pharmaceuticals
  • Ovid Therapeutics
  • PTC Therapeutics
  • Zogenix
  • MORE

Report Highlights

  • In the coming years, Dravet Syndrome market scenario is expected to alter across the 7MM due shift of focus from symptomatic treatment and maturation of the pipeline to include disease-modifying treatment.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Dravet Syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Dravet Syndrome Pipeline Analysis
  • Dravet Syndrome Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Dravet Syndrome Report Key Strengths

  • 11 years Forecast
  • 7MM Coverage
  • Dravet Syndrome Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Dravet Syndrome Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Dravet Syndrome market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Dravet Syndrome total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Dravet Syndrome market size during the forecast period (2017-2030)?
  • At what CAGR, the Dravet Syndrome market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Dravet Syndrome market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Dravet Syndrome market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Dravet Syndrome?
  • What is the historical Dravet Syndrome patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Dravet Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dravet Syndrome?
  • Out of all 7MM countries, which country would have the highest incidence population of Dravet Syndrome during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Dravet Syndrome treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Dravet Syndrome in the USA, Europe, and Japan?
  • What are the Dravet Syndrome marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Dravet Syndrome?
  • How many therapies are developed by each company for Dravet Syndrome treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Dravet Syndrome treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dravet Syndrome therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Dravet Syndrome and their status?
  • What are the key designations that have been granted for the emerging therapies for Dravet Syndrome?
  • What are the global historical and forecasted market of Dravet Syndrome?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Dravet Syndrome market
  • To understand the future market competition in the Dravet Syndrome market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Dravet Syndrome market
  • To understand the future market competition in the Dravet Syndrome market

Which geography accounted for the largest Dravet Syndrome market size?

United States accounted for the largest Dravet Syndrome market size.

What is forecasted Dravet Syndrome market size in 2030?

estimates an increase in DS Market Size during the study period, 2017-2030.

What are the present Dravet Syndrome market drivers?

Increasing research and developmental activities in order to find novel targets and improving current challenges along with increasing awareness among the people.

What are the Dravet Syndrome market barriers?

Paucity of data regarding effective strategies, comparatively reduced focus along with diagnostic challenges.

How many companies are developing drugs for Dravet Syndrome?

Currently three key pharma players are developing drug for Dravet Syndrome.

Which are the leading companies in Dravet Syndrome market?

Key Players - Ovid Therapeutics/Takeda, PTC Therapeutics and Zogenix.

How is epidemiology segmented for Dravet Syndrome?

Incidence of Dravet Syndrome, Mutation positive cases of Dravet Syndrome, Mutational cases associated with DS by Types and Class, Seizures associated cases with DS, Gender-specific cases and Age-specific cases of Dravet Syndrome.

Note: Product cover images may vary from those shown
  • Biocodex
  • GW Pharmaceuticals
  • Zogenix
  • Ovid Therapeutics
  • PTC Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll